Publication for ICOS and BTLA

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	ICOS	inducible T cell costimulator	29851			[link]
hsa	BTLA	B and T lymphocyte associated	151888

Pubmed ID	Priority	Text
27577071	0.97	B-and T-lymphocyte attenuator (BTLA), CD28, CD27, TIGIT and CD278, in circulating CD4+ and CD8+ T cells that were derived from normal donors (n = 10) or esophageal cancer patients (n = 10, Figure 1).
	0.97	CD278, CD200, PD-1, BTLA, CD137L, CD273 and CD274) in CD4+ and CD8+ T cells of normal donors' peripheral blood mononuclear cells (PBMC) and esophageal cancer patients' PBMC.
	0.54	CD278, CD273 and CD274 on patient CD8+ T cells) showing expression and mean fluorescence intensity (MFI) of CD158, CTLA-4, CD28, CD27, CD160, TIM-3, CD137, TIGIT, CD278, CD200, PD-1, BTLA, CD137L, CD273 and CD274 in CD4+ and CD8+ T cells.
27911271	0.97	BTLA, ITGAL, CTLA4, ICOS, PDCD1, and VTCN1 were reported as breast cancer risk mutations in previous studies (Supplementary Table S6).
19247441	0.96	BTLA and ICOS expressions by percentage and MFI in total CD8 T cells from blood and in liver-derived CD8 T cell subsets (PD-1-CTLA-4-, PD-1+CTLA-4-, PD-1+CTLA-4+) ex vivo from 5 chronic HCV patients.
	0.96	BTLA and ICOS expression in PD-1+CTLA-4+ (Red), PD-1+CTLA-4- (Green) and PD-1-CTLA-4- (Blue) CD8 T cell subsets relative to isotype control (gray shade) in the histograms on the right.
	0.93	ICOS and BTLA expression levels were generally low, although a slight increase in ICOS expression was observed in PD-1+CTLA-4+ subset compared to others (median 2.4% vs 0.5% vs 0.1%, p = 0.049).
	0.92	ICOS or BTLA.
	0.91	ICOS or BTLA.
	0.78	BTLA+ (intrahepatic CD8 subsets: 0.1% vs. 0.4% vs. 0.3%, p = 0.364); %ICOS+ (intrahepatic CD8 subsets: 0.1% vs. 0.5% vs. 2.4%, p = 0.049); ICOS MFI (intrahepatic CD8 subsets: 43 vs. 50 vs. 78, p = 0.021).
28428203	0.96	ICOS, PD1, BCL6, BTLA, and SAP, among other Tfh markers.
	0.69	ICOS, BTLA, SAP, CD200, CXCL13, IL-21, C-MAF, BCL6, and BLIMP1) by TSLP-DC-induced CXCR5hiPD1hi cells was similar to tonsillar Tfh and GC Tfh cells.
24030473	0.95	ICOS, BTLA, and Fas were higher in the TFH cell subset (Figure 5D).
22753927	0.91	ICOS, CD40 ligand (CD40L), OX40, PD-1, BTLA and CD84, the cytokine IL-21, the cytoplasmic adaptor protein SLAM-associated protein (SAP), and the transcription factors Bcl-6 and c-Maf.
30984188	0.91	ICOS), programmed death-1 (PD-1), and B and T-lymphocyte attenuator (BTLA); and the second is the tumor necrosis factor receptor (TNFR) superfamily (TNFRSF), which includes CD27, CD30, 4-1BB, herpesvirus entry mediator (HVEM), CD40, and OX40 (Table 1).
27314219	0.87	ICOS and BTLA receptors.
30319637	0.75	BTLA and VISTA, and of the latter 4-1BB (CD137), OX40 (CD134), ICOS, and CD40.
24198743	0.72	ICOS, and BTLA that transmit co-signals into T cells (Fig. 1).
21074063	0.69	ICOS, and BTLA.
22548114	0.66	ICOS; CD278), and B- and T-lymphocyte attenuator (BTLA; CD272); (2) CD2/signaling lymphocyte activation molecule (SLAM) family including SLAM (CD150), 2B4 (CD244), and CD48; (3) Ig family including T-cell immunoglobulin mucin-3 (TIM-3), CD160, and Lymphocyte-activation gene 3 (Lag-3); and (4) TNF-receptor superfamily including CD27.
29995563	0.62	BTLA, TIGIT, OX40, 4-1BB, CD27 and ICOS.